Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Two-treatment, Two-period, Crossover, Single-dose, Subcutaneous Injection Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Manufactured by Nanogen Pharmaceutical Biotechnology Joint Stock Company With Eprex 4000 U Manufactured by Cilag AG in Healthy Volunteers

NCT06919861 is registered in ClinicalTrials.gov with Nanogen Pharmaceutical Biotechnology Joint Stock Company as lead sponsor.

NCT NCT06919861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06919861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Two-treatment, Two-period, Crossover, Single-dose, Subcutaneous Injection Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Manufactured by Nanogen Pharmaceutical Biotechnology Joint Stock Company With Eprex 4000 U Manufactured by Cilag AG in Healthy Volunteers
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
44 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics and pharmacodynamics in healthy volunteers